Recent research have converged on the convergence of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and dopaminergic signaling. While GCGR activators are increasingly employed for treating type 2 diabetes, their emerging effects on reward circuits, specific